Valeo Financial Advisors LLC Decreases Stake in Johnson & Johnson $JNJ

Valeo Financial Advisors LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 38.5% during the second quarter, HoldingsChannel reports. The fund owned 79,637 shares of the company’s stock after selling 49,749 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Johnson & Johnson were worth $12,165,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at approximately $27,000. Semmax Financial Advisors Inc. raised its holdings in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the period. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth $35,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the first quarter worth $48,000. Finally, Vermillion & White Wealth Management Group LLC grew its position in shares of Johnson & Johnson by 66.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after purchasing an additional 150 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.3%

Shares of JNJ opened at $214.41 on Tuesday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.19. The company has a market capitalization of $516.58 billion, a P/E ratio of 20.70, a P/E/G ratio of 2.36 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm’s 50 day simple moving average is $196.61 and its 200 day simple moving average is $177.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on JNJ shares. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday. Citigroup raised their price objective on shares of Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research report on Thursday. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. Finally, Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $208.35.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.